Skip to content
Veliparib
Veliparib is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XK: Poly (adp-ribose) polymerase (parp) inhibitors
— L01XK05: Veliparib
HCPCS
No data
Clinical
Clinical Trials
103 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C501471—123
Ovarian neoplasmsD010051EFO_0003893C561561——20
Triple negative breast neoplasmsD064726641—314
Non-small-cell lung carcinomaD002289552——9
GlioblastomaD005909EFO_0000515131——3
GliosarcomaD018316121——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C80143——219
Fallopian tube neoplasmsD00518583———10
Pancreatic neoplasmsD010190EFO_0003860C2563———8
AstrocytomaD001254EFO_000027132———4
Small cell lung carcinomaD05575233———4
Non-hodgkin lymphomaD008228C85.931———3
MelanomaD00854521———3
GliomaD005910EFO_000052022———3
Myelodysplastic syndromesD009190D4621———3
Myeloid leukemia acuteD015470C92.021———3
Show 40 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Stomach neoplasmsD013274EFO_0003897C164————4
Colonic neoplasmsD003110C184————4
Lung neoplasmsD008175C34.904————4
Male breast neoplasmsD0185673————3
LymphomaD008223C85.93————3
Endometrioid carcinomaD0182692————2
Hereditary breast and ovarian cancer syndromeD0613252————2
MedulloblastomaD0085272————2
EpendymomaD0048062————2
Primitive neuroectodermal tumorsD0182422————2
Show 45 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVELIPARIB
INNveliparib
Description
Veliparib is a benzimidazole substituted with a carbamoyl group at C-4 and a (2R)-2-methylpyrrolidin-2-yl moiety at C-2. It is a potent, orally bioavailable PARP inhibitor. It has a role as an EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor.
Classification
Small molecule
Drug classpoly-ADP-ribose polymerase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[C@]1(c2nc3c(C(N)=O)cccc3[nH]2)CCCN1
Identifiers
PDB—
CAS-ID912444-00-9
RxCUI—
ChEMBL IDCHEMBL506871
ChEBI ID62880
PubChem CID11960529
DrugBankDB07232
UNII ID01O4K0631N (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 3,546 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
432 adverse events reported
View more details